Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Organon & Co. Common Stock — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.96 (market cap $7.03B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Norwegian Cruise Line Holdings Ltd is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 69 Days and Organon & Co. Common Stock for 0 Days on average.
| NCLH | OGN | |
|---|---|---|
Market Cap | $7.03B | $3.62B |
Volume | 12,698,429 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $13.81 |
52-Week Low | $14.12 | $5.70 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $21.85B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $14.87, down 3.13% today, with mixed technical signals showing neutral overall but bearish moving averages. The company demonstrates strong fundamental recovery with Q2 2026 EPS beating expectations at $0.48 versus $0.41, and maintains positive cash flow trends. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, while facing yield pressure through 2027.
NCLH presents a compelling value opportunity with a low P/E of 9.28 and strong analyst consensus price target of $20.86 (40% upside), though elevated debt levels and Caribbean pricing pressure pose near-term risks. The stock's investment case hinges on continued operational execution and demand stabilization amid industry headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
